Express Mail Label No.: ED 908733412 US Attorney Docket No.: 100870-1P US

**10**/550039

Approved for use through 03/31/2007. OMB 0651-0021 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)

**Docket Number** (Optional) 100870-1P-US

First Named Inventor: Michael Barry Gravestock

International (PCT) Application No.: PCT/GB2004/001119

U.S. Application No.: (if known)

Filed: March 20, 2003

Title: Antibacterial 1,3-Oxazolidin-2-one Derivatives

Attention: PCT Legal Staff

Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).

## APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

, , , , , , , , , , , , , , , , , , , ,
1. Petition fee Small entity - fee \$(37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.
Other than small entity - fee \$ See 1 (37 CFR 1.17(m))
Properventy
A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of Form PTO-1390 (identify type of reply):
$\overline{\mathbf{X}}$ has been filed previously on See 2 in Addendum
is enclosed herewith.

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If your need assistance-in completing the form, call 1-800-PTO-9199 and select option 2.

10/25/2005 LLANDGRA 00000002 10550039

01 FC:1453

1500.00 DA

PTO/SB/64/PCT (12-04)
Approved for use through 03/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee		
Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.		
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).		
<ol> <li>Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.</li> </ol>		
WARNING: Information on this form may become public. Credit cabe included on this form. Provide credit card information and aut		
	Sept 7.3	
Signature	Date	
Heidi M. Berven	48,951	
Typed or Printed Name	Registration Number, if applicable	
AstraZeneca R&D Boston	781-839-4336	
Address	Telephone Number	
35 Gatehouse Drive Waltham MA 02451		
Address		
Enclosures: X Response Fee Payment		
Terminal Disclaimer		
Other (please identify): Copies of Form 1390 and		
Terminal Disclaimer  Nother (please identify): Copies of Form 1390 and associated information		